MDXG vs. NARI, PRCT, NVST, NVCR, IRTC, LIVN, WRBY, ENOV, TNDM, and TMDX
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Inari Medical (NARI), PROCEPT BioRobotics (PRCT), Envista (NVST), NovoCure (NVCR), iRhythm Technologies (IRTC), LivaNova (LIVN), Warby Parker (WRBY), Enovis (ENOV), Tandem Diabetes Care (TNDM), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.
MiMedx Group vs.
Inari Medical (NASDAQ:NARI) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.
91.0% of Inari Medical shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by company insiders. Comparatively, 1.3% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Inari Medical had 3 more articles in the media than MiMedx Group. MarketBeat recorded 3 mentions for Inari Medical and 0 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.88 beat Inari Medical's score of 0.06 indicating that MiMedx Group is being referred to more favorably in the news media.
Inari Medical presently has a consensus price target of $68.00, indicating a potential downside of 14.52%. MiMedx Group has a consensus price target of $12.00, indicating a potential upside of 31.58%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Inari Medical.
MiMedx Group has a net margin of 23.86% compared to Inari Medical's net margin of -13.68%. MiMedx Group's return on equity of 26.21% beat Inari Medical's return on equity.
Inari Medical has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.
MiMedx Group has lower revenue, but higher earnings than Inari Medical. Inari Medical is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Inari Medical received 21 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 81.82% of users gave MiMedx Group an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.
Summary
MiMedx Group beats Inari Medical on 12 of the 18 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
This page (NASDAQ:MDXG) was last updated on 1/20/2025 by MarketBeat.com Staff
